Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure

American Journal of Cardiology

Volumn 83, Issue 8, 1999, Pages 1201-1205

  Lowes, Brian D ^a   Gill, Edward A ^c   Abraham, William T ^c   Larrain, Jorge Rodriquez ^b   Robertson, Alastair D ^c   Bristow, Michael R ^b   Gilbert, Edward M ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MYOCARDIAL CONTRACTION; PROPANOLAMINES; PROSPECTIVE STUDIES; RADIONUCLIDE VENTRICULOGRAPHY; STROKE VOLUME; TREATMENT OUTCOME;

EID: 0033561146     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00059-4     Document Type: Article

References (11)

1. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biologic properties of the chronically failing heart a new era in the treatment of heart failure . Circulation. 94:1996;2285-2296.
2. Bristow M.R., Larrabee P., Minobe W., Roden R.L., Skerl L., Klein J., Handwerger D., Port J.D., Muller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 19:1992;S68-S80.
3. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., White M., Mealey P., Larrabee P., Bristow M.R. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 94:1996;2817-2825.
4. Olsen S.L., Gilbert E.M., Renlund D.G., Taylor D.O., Yanowitz F.D., Bristow M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
5. Schiller N.B., Skioldebrand C.G., Schiller E.J. Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation. 68:1983;210-216.
6. Zhang J., McDonald K.M. Bioenergetic consequences of left ventricular remodeling. Circulation. 92:1995;1011-1019.
7. Eichhorn E.J., Heesh C.M., Barnett J.H., Alvarez L.G., Fass S.M., Grayburn P.A., Hatfield B.A., Marcoux L.G., Malloy C.R. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy a randomized double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
8. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
9. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
10. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockage. J Am Coll Cardiol. 25:1995;1154-1161.
11. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic disease. J Am Coll Cardiol. 29:1997;1060-1065.